Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation, Liaoning Cancer immune peptide drug Engineering Technology Research Center, Shenyang, China.
Cell Prolif. 2021 May;54(5):e13025. doi: 10.1111/cpr.13025. Epub 2021 Mar 22.
The peptide-based therapeutic cancer vaccines have attracted enormous attention in recent years as one of the effective treatments of tumour immunotherapy. Most of peptide-based vaccines are based on epitope peptides stimulating CD8 T cells or CD4 T helper cells to target tumour-associated antigens (TAAs) or tumour-specific antigens (TSAs). Some adjuvants and nanomaterials have been exploited to optimize the efficiency of immune response of the epitope peptide to improve its clinical application. At present, numerous peptide-based therapeutic cancer vaccines have been developed and achieved significant clinical benefits. Similarly, the combination of peptide-based vaccines and other therapies has demonstrated a superior efficacy in improving anti-cancer activity. We delve deeper into the choices of targets, design and screening of epitope peptides, clinical efficacy and adverse events of peptide-based vaccines, and strategies combination of peptide-based therapeutic cancer vaccines and other therapies. The review will provide a detailed overview and basis for future clinical application of peptide-based therapeutic cancer vaccines.
近年来，基于肽的治疗性癌症疫苗作为肿瘤免疫治疗的有效方法之一引起了极大的关注。大多数基于肽的疫苗都是基于刺激 CD8 T 细胞或 CD4 T 辅助细胞的表位肽，以靶向肿瘤相关抗原 (TAA) 或肿瘤特异性抗原 (TSA)。一些佐剂和纳米材料已被开发利用，以优化表位肽的免疫反应效率，从而提高其临床应用。目前，已经开发了许多基于肽的治疗性癌症疫苗，并取得了显著的临床获益。同样，基于肽的疫苗与其他疗法的联合应用在提高抗癌活性方面显示出了更好的疗效。我们深入探讨了基于肽的治疗性癌症疫苗的靶点选择、表位肽的设计和筛选、临床疗效和不良事件，以及与其他疗法的联合策略。本文综述为基于肽的治疗性癌症疫苗的未来临床应用提供了详细的概述和基础。
